AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14758573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11812703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringers solution (RL)
Number of subjects: 42
Study 11812703 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (SS)
Number of subjects: 42
Study 9826134 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed endoscopic monitoring with eventual retreatment
Number of subjects: 105
Study 9826134 — intervention group
Group type: COMPARATOR
Intervention: Control group with close monitoring and second endoscopy only upon evidence of recurrent bleeding
Number of subjects: 105
Study 9826134 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed endoscopic monitoring
Number of subjects: 105
Study 9826134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 7925517 — intervention group
Group type: EXPERIMENTAL
Intervention: pimobendan (average 10.3 mg.day‐1, n = 119)
Number of subjects: 242
Study 7925517 — intervention group
Group type: COMPARATOR
Intervention: enalapril (average 10.7 mg.day‐1, n = 123)
Number of subjects: 242
Study 2531972 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied local anaesthetic cream (EMLA)
Number of subjects: 8
Study 2531972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1101247 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxuridine 5% in dimethyl sulphoxide (DMSO)
Number of subjects: 50
Study 1101247 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxuridine 40% in dimethyl sulphoxide (DMSO)
Number of subjects: 50
Study 1101247 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxuridine (both concentrations)
Number of subjects: 50
Study 31745762 — intervention group
Group type: COMPARATOR
Intervention: Natural cycles (N group)
Number of subjects: 12
Study 31745762 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated cycles (S group)
Number of subjects: 12
Study 31745762 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (P, N, S)
Number of subjects: 12
Study 29743149 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered exercise, education, and pain coping skills training
Number of subjects: 148
Study 29743149 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered education alone
Number of subjects: 148
Study 28192673 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 100 mg·day‐1
Number of subjects: 24
Study 28192673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26317257 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 232
Study 26317257 — intervention group
Group type: EXPERIMENTAL
Intervention: Any antiplatelet/anticoagulant therapy
Number of subjects: 232
Study 26317257 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 232
Study 26317257 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors/angiotensin II antagonist therapy
Number of subjects: 232
Study 26317257 — intervention group
Group type: EXPERIMENTAL
Intervention: Any method to stop smoking, lipid lowering agents, antiplatelet and/or anticoagulation therapy, and any kind of exercise program
Number of subjects: 232
Study 26317257 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program and use of cilostazol
Number of subjects: 232
Study 26317257 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 232
Study 24340989 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.4 mg/kg/hr rocuronium bromide (esmeron) in group 1 (n = 14)
Number of subjects: 46
Study 24340989 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of 0.15 mg/kg/hr esmeron in group 2 (n = 11)
Number of subjects: 46
Study 24340989 — intervention group
Group type: EXPERIMENTAL
Intervention: Decurarization with proserin in group 3 (n = 11)
Number of subjects: 46
Study 24340989 — intervention group
Group type: EXPERIMENTAL
Intervention: Decurarization with sugammadex in group 4 (n = 10)
Number of subjects: 46
Study 22025580 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 2
Study 22025580 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture change (sitting to supine)
Number of subjects: 2
Study 22025580 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture change
Number of subjects: 2
Study 22025580 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure treatment
Number of subjects: 2
Study 18454656 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive regimen for periodontally healthy subjects
Number of subjects: 112
Study 18454656 — intervention group
Group type: COMPARATOR
Intervention: Maintenance program for periodontitis subjects
Number of subjects: 112
Study 16832022 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + P
Number of subjects: 4262
Study 16832022 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE
Number of subjects: 4262
Study 15114087 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath-1H) and low-dose Tacrolimus (Tac)
Number of subjects: 40
Study 15114087 — intervention group
Group type: COMPARATOR
Intervention: Standard Tac and steroids protocol
Number of subjects: 40
Study 11405312 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting
Number of subjects: 0
Study 11405312 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals plus feedback
Number of subjects: 0
Study 11405312 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 9675658 — intervention group
Group type: EXPERIMENTAL
Intervention: TATA-box variant in the promoter of uridine diphosphate glucuronosyltransferase in patients with Gilbert's syndrome
Number of subjects: 46
Study 9675658 — intervention group
Group type: COMPARATOR
Intervention: TATA-box variant in the promoter of uridine diphosphate glucuronosyltransferase in controls
Number of subjects: 46
Study 9675658 — intervention group
Group type: COMPARATOR
Intervention: Homozygous controls for the TATA-box variant
Number of subjects: 46
Study 8015796 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons with considerable or average expertise
Number of subjects: 146
Study 8015796 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 146
Study 8015796 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 146
Study 2686919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin
Number of subjects: 67
Study 2686919 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole/gentamicin
Number of subjects: 67
Study 1089521 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin (Trasylol)
Number of subjects: 164
Study 1089521 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 164
Study 31686255 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power therapeutic ultrasound with neutral gel
Number of subjects: 90
Study 31686255 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power therapeutic ultrasound with 5% lipolytic active caffeine gel (phonophoresis)
Number of subjects: 90
Study 31686255 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral gel)
Number of subjects: 90
Study 30609988 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage algorithm display using Smart Glasses
Number of subjects: 31
Study 30609988 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical contact with senior emergency physician using Smart Glasses
Number of subjects: 31
Study 30609988 — intervention group
Group type: COMPARATOR
Intervention: Conventional triage without technical support (control group)
Number of subjects: 31
Study 28182252 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfine merino wool ensembles
Number of subjects: 39
Study 28182252 — intervention group
Group type: COMPARATOR
Intervention: Standard cotton clothing
Number of subjects: 39
Study 25245113 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners Together in Health (PaTH) intervention
Number of subjects: 34
Study 25245113 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study 25245113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 23863908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial intervention
Number of subjects: 1461
Study 23863908 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1461
Study 21779579 — intervention group
Group type: EXPERIMENTAL
Intervention: 67 mg caffeine
Number of subjects: 12
Study 21779579 — intervention group
Group type: EXPERIMENTAL
Intervention: 133 mg caffeine
Number of subjects: 12
Study 21779579 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 12
Study 21779579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19427574 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cranial electrical stimulation (CES)
Number of subjects: 38
Study 19427574 — intervention group
Group type: COMPARATOR
Intervention: Sham cranial electrical stimulation (CES)
Number of subjects: 38
Study 16764868 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa)
Number of subjects: 12
Study 16764868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15572016 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning privilege during bed rest
Number of subjects: 419
Study 15572016 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 419
Study 15572016 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 419
Study 12184352 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for back pain
Number of subjects: 0
Study 12184352 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ANCOVA
Number of subjects: 0
Study 9265993 — intervention group
Group type: EXPERIMENTAL
Intervention: + training in relaxation during both sensitization and challenge phase
Number of subjects: 4
Study 9265993 — intervention group
Group type: COMPARATOR
Intervention: − training in relaxation during challenge phase only
Number of subjects: 4
Study 9265993 — intervention group
Group type: EXPERIMENTAL
Intervention: High hypnotic susceptible subjects
Number of subjects: 4
Study 9265993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hypnotic susceptible subjects
Number of subjects: 4
Study 8324040 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal EMG biofeedback
Number of subjects: 45
Study 8324040 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback to increase EEG alpha
Number of subjects: 45
Study 8324040 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback to decrease EEG alpha
Number of subjects: 45
Study 8324040 — intervention group
Group type: COMPARATOR
Intervention: Pseudomeditation control
Number of subjects: 45
Study 8324040 — intervention group
Group type: EXPERIMENTAL
Intervention: All treated subjects
Number of subjects: 45
Study 3521272 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 225
Study 3521272 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 225
Study 31225820 — intervention group
Group type: EXPERIMENTAL
Intervention: CI532 with intraoperative intracochlear electrocochleography (ECochG)
Number of subjects: 15
Study 31225820 — intervention group
Group type: EXPERIMENTAL
Intervention: CI522 with intraoperative intracochlear electrocochleography (ECochG)
Number of subjects: 15
Study 31225820 — intervention group
Group type: EXPERIMENTAL
Intervention: ECochG monitoring during CI electrode insertion
Number of subjects: 15
Study 31225820 — intervention group
Group type: EXPERIMENTAL
Intervention: ECochG amplitude changes during insertion
Number of subjects: 15
Study 28364494 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated sleep time (60%-130% of habitual sleep time)
Number of subjects: 50
Study 27483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 927
Study 27483458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 927
Study 27483458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 25081728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy combined with 'Jianpi Huayu Therapy' (treatment group)
Number of subjects: 120
Study 25081728 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone (control group)
Number of subjects: 120
Study 22537179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (Partner Schools)
Number of subjects: 58
Study 22537179 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intensive intervention (Associate Schools)
Number of subjects: 58
Study 22537179 — intervention group
Group type: COMPARATOR
Intervention: Comparison group with delayed intervention
Number of subjects: 58
Study 19864968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone treatment post-implementation of clinical practice guideline (CPG)
Number of subjects: 127
Study 19864968 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone treatment pre-implementation of clinical practice guideline (CPG)
Number of subjects: 127
Study 17453330 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative thinking
Number of subjects: 52
Study 15173671 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong training program (30 minutes daily for one month)
Number of subjects: 29
Study 15173671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 11566656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy product consumption >2.5 servings daily
Number of subjects: 20885
Study 11566656 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake >600 mg/d from dairy products
Number of subjects: 20885
Study 11566656 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk consumption >600 mg Ca/d
Number of subjects: 20885
Study 9445231 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide, 100 microg TID SQ for 5 days after transplant (n = 10)
Number of subjects: 17
Study 9445231 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control group, n = 7)
Number of subjects: 17
Study 9445231 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide treatment (n = 10)
Number of subjects: 17
Study 9445231 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 17
Study 7987998 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m2 per day) combined with cyclophosphamide (1500 mg/m2 per day), thiotepa (120 mg/m2 per day), and mesna (3 g/day) for 4 consecutive days
Number of subjects: 9
Study 2729934 — intervention group
Group type: COMPARATOR
Intervention: Ocular administration of recombinant alpha interferon; dosages not specified.
Number of subjects: 0
Study 2729934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group); details not specified.
Number of subjects: 0
Study 5336037 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine treatment
Number of subjects: 0
Study 31115192 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine supportive care plus CIM intervention (nurse-led supportive care intervention using Complementary and Integrative Medicine)
Number of subjects: 251
Study 31115192 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone (control group)
Number of subjects: 251
Study 28323725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insertion
Number of subjects: 66
Study 28323725 — intervention group
Group type: COMPARATOR
Intervention: Nasal insertion
Number of subjects: 66
Study 25938633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/d
Number of subjects: 36
Study 25938633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23890686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologically‐Based Treatment (n=30)
Number of subjects: 60
Study 23890686 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n=30)
Number of subjects: 60
Study 21418868 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT plus internal drainage or laparotomy
Number of subjects: 65
Study 21418868 — intervention group
Group type: COMPARATOR
Intervention: Control group (internal drainage or laparotomy only)
Number of subjects: 65
Study 21418868 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT
Number of subjects: 65
Study 19747427 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (240 mg in four doses)
Number of subjects: 36
Study 19747427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17760317 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance levels in psychotherapy
Number of subjects: 44
Study 17760317 — intervention group
Group type: EXPERIMENTAL
Intervention: Local rupture-and-repair patterns
Number of subjects: 44
Study 17760317 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear trends in alliance ratings
Number of subjects: 44
Study 17760317 — intervention group
Group type: EXPERIMENTAL
Intervention: Global high-low-high pattern
Number of subjects: 44
Study 17760317 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment differences
Number of subjects: 44
Study 15202379 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.5 g of Minolest®
Number of subjects: 25
Study 15202379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15061347 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-assisted cognitive behavior therapy (MACT)
Number of subjects: 480
Study 15061347 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 480
Study 15061347 — intervention group
Group type: EXPERIMENTAL
Intervention: MACT
Number of subjects: 480
Study 10465667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror intervention placed on the right side of the patient
Number of subjects: 0
Study 10465667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror intervention placed in the coronal position with objects behind the head
Number of subjects: 0
Study 10465667 — intervention group
Group type: COMPARATOR
Intervention: Mirror intervention
Number of subjects: 0
Study 7495235 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus vitamin E [0.4 g (400 IU)/d; n = 52]
Number of subjects: 100
Study 7495235 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (325 mg; n = 48)
Number of subjects: 100
Study 7495235 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus vitamin E
Number of subjects: 100
Study 7495235 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 100
Study 2044754 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient Family Intervention (IFI)
Number of subjects: 169
Study 7011250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline (noneuphorigenic psychostimulant drug)
Number of subjects: 0
Study 7011250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7011250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline (for subgroup with parents describing them in the 95th percentile of childhood hyperactivity)
Number of subjects: 0
Study 7011250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for subgroup with parents describing them in the 95th percentile of childhood hyperactivity)
Number of subjects: 0
Study 31075364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 90
Study 31075364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29452372 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal influenza vaccination at 17-25 weeks gestation
Number of subjects: 3646
Study 29452372 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal influenza vaccination at 26-34 weeks gestation
Number of subjects: 3646
Study 29452372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3646
Study 27312203 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD combinations or biologic agents
Number of subjects: 672
Study 27312203 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy or steroid and DMARD combinations
Number of subjects: 672
Study 25227564 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine (6 g/day)
Number of subjects: 72
Study 25227564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 22428809 — intervention group
Group type: EXPERIMENTAL
Intervention: MI+HealthCall
Number of subjects: 33
Study 22428809 — intervention group
Group type: COMPARATOR
Intervention: MI-only
Number of subjects: 33
Study 20023571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 20023571 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted agents (e.g., receptor tyrosine kinase inhibitors)
Number of subjects: 0
Study 18058408 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone alone
Number of subjects: 0
Study 18058408 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label disulfiram and naltrexone
Number of subjects: 0
Study 18058408 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label disulfiram and placebo
Number of subjects: 0
Study 18058408 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 0
Study 16131600 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (1.2 IU/day for men and 1.8 IU/day for women)
Number of subjects: 55
Study 16131600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11957004 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSealTM Matrix (FM)
Number of subjects: 0
Study 11957004 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam(R) plus thrombin (GT)
Number of subjects: 0
Study 10423715 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA)
Number of subjects: 104
Study 10423715 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/cyproterone acetate (EV/CPA)
Number of subjects: 104
Study 7474008 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network prediction
Number of subjects: 580
Study 31679924 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger Kazoo Intensive Short-Term Vocal Therapy
Number of subjects: 41
Study 31679924 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41